Here are four things to know.
1. Pfizer is working with financial advisors at JPMorgan Chase & Co., although the divestiture is still in a preliminary stage, the source said.
2. The drugs produce sales of more than $700 million and are valued at more than $2 billion, according to the report. About 40 percent of the sales occur in the U.S. and 45 percent occur in Europe.
3. Pfizer prefers to divest the medications through a single deal, as opposed to selling off each drug individually, reports Bloomberg.
4. Representatives from Pfizer and JPMorgan declined Bloomberg’s request for comment.
More articles on supply chain:
This week’s 5 must-reads for supply chain leaders
A new framework for measuring the true value of drugs: 5 takeaways
Bloomberg: Medtronic arranging sale of medical supplies business
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.